The Nursing Care Quality Assurance Commission supports Federation of State Medical Boards’ statement released on July 29, 2021 regarding COVID-19 vaccine misinformation.

“Physicians who generate and spread COVID-19 vaccine misinformation or disinformation are risking disciplinary action by state medical boards, including the suspension or revocation of their medical license."

The NCQAC expands this statement to include nurses in Washington State and does not limit this perspective to vaccines but broadly applies this standard to all misinformation regarding COVID-19 treatments and preventive measures such as masking. Nurses who generate and spread COVID-19 misinformation, or disinformation, erode the public trust in the nursing profession and endangers patients.

The NCQAC bases masking and vaccination safety on expert recommendations from the U.S. Centers for Disease Control and Prevention (CDC) and the Washington State Department of Health (DOH).

Well researched article including many references. Dr. Ozaki, Chairman of the Tokyo Medical Association discusses the positive effects of ivermectin (IVM) used in early treatment. Covers the reluctance of scientists to conduct testing on IVM due to reliance on opinions of big organizations such as WHO. Also covers the intentional limiting of distribution by Merk, the pharmaceutical company that held the (now expired) patent. Dr. Ozaki believes IVM should be given to everyone in Japan to use if they test positive. He also states that with proper treatment, coronavirus should be downgraded to level 5, similar to the flu.

Ivermectin is on the World Health Organization’s essential drug list. In 1987, the pharmaceutical company Merck established the Mectizan (ivermectin) donation program. This program is considered an exemplar among drug donation arrangements. Three hundred million people have been treated with ivermectin, donated by Merck in more than 30 countries. Yet US media decries it as only a "horse dewormer". This article shows an example of censorship of a potentially helpful treatment.

This preprint of a large study (384,543 individuals) in the UK concludes that, regardless of which vaccine is used, the immunity conferred is similar to natural immunity acquired through prior infection. This 39 page study details methods, statistics and complete analysis of this very large cohort.

"We investigated the effectiveness of the vaccines in a large community-based survey of randomly selected households across the UK. We found that the effectiveness of [vaccines] against any infections (new PCR positives) and infections with symptoms or high viral burden is reduced with the Delta variant. A single dose of ... [one brand] vaccine had similar or greater effectiveness compared to a single dose of [other vaccines.] Effectiveness of two doses remains at least as great as protection afforded by prior natural infection."

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

Small Belgian study reports findings:

accumulation of pathobionts on the masks due to human saliva and exhaled breath represents a possible underestimated biosafety concern...

We also tested the accumulation of antibiotic-resistant strains on the face masks, as antibiotic-resistant strains are a worldwide problem...

Approximately 43% of selected colonies were resistant to at least one of the two tested antibiotics (ampicillin and erythromycin) and 6% was even resistant to both.

This pilot study was performed to evaluate the rapidity of viral clearance and safety of a 5-day course of ivermectin or a single dose of ivermectin plus a 5-day course of doxycycline in the treatment of mild COVID-19 in adults.

SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021.

Conclusions This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant.

Study examines viral load in vaccinated (V) and unvaccinated (U) people. Also compares viral load in symptomatic and asymptomatic individuals. Study concludes that, in asymptomatic people, more vaccinated had detectible virual load compared to unvaccinated (82%V, and 29%U). For the symptomatic, there was virtually no difference (69%V, and 68%U). There was no difference in time to onset of symptoms

This shows that by the time symptoms do appear, both vaccinated and unvaccinated are equally likely to be infected. But for the asymptomatic, more vaccinated people have the capacity to carry the virus without showing symptoms. One might consider this a good argument to classify the vaccine as a biologic treatment rather than an immunization.

FDA Approval for Comirnaty - the Pfizer COVID-19 product marketed as a vaccine. The following quote reveals certain notable inconsistencies:

• states the product is indicated ... to prevent coronavirus disease 2019. (It does not do this)
• is approved under a "biologics" license (special class of medication - not a vaccine)
• Further testing required under this license extends until 2027.

We are issuing Department of Health and Human Services U.S. License No. 2229 to BioNTech Manufacturing GmbH, Mainz, Germany, under the provisions of section 351(a) of the PHS Act controlling the manufacture and sale of biological products.

Under this license, you are authorized to manufacture the product, COVID-19 Vaccine, mRNA, which is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.

The review of this product was associated with the following National Clinical Trial (NCT) numbers: NCT04368728 and NCT04380701.